Why Peptide Delivery Platform Depth Is Measured in Foundational Patents Not Published Papers
Patents, not papers, show who owns a peptide delivery breakthrough.
Patents, not papers, show who owns a peptide delivery breakthrough.
Its test is whether carriers, targets, and human translation plans cohere.
Intranasal peptides reach the brain differently than IV doses.
A route-by-route comparison shows nasal delivery's promise hinges on human data.
Continuation claims can lock in route, payload, and target, within limits.
Shared nanoparticle design decides which brain targets and peptides a pipeline can reach.
Nanoparticle nose-to-brain delivery best matches peptide needs, but human proof is missing.
Designing nanoparticles to deliver peptides across the blood-brain barrier through the nose.
Two nanoparticle platforms vie to deliver GLP-1 peptides to the brain safely.
How particle material, size, and coatings decide intranasal GLP-1 delivery.
Approved nasal CNS drugs set a precedent, but peptides still need proof.